CMS121 |
Catalog No.GC40632
One-Click Copy Product Info
|
CMS121 es un inhibidor de la acetyl-CoA carboxylase 1 (ACC1) activa por vía oral
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1353224-53-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
CMS121 es un inhibidor de la acetyl-CoA carboxylase 1 (ACC1) activa por vía oral [1]. CMS121 ejerce potentes efectos neuroprotectores, antiinflamatorios, antioxidantes y protectores renales al elevar los niveles de acetyl-CoA y activar AMPK [2-3]. CMS121 está destinado de trastornos neurodegenerativos similares al Alzheimer[4].
En las células SH-SY5Y, CMS121 (5μM; 48h) reduce la infectividad de las partículas virales de HSV-1[5]. En los hepatocytes, CMS12 (1μM; 24h) aumenta los niveles de ac-STAT3 y p-STAT3[6].
En ratones male db/db macho, el tratamiento a largo plazo con CMS121 (9.4mg/kg, 18.8mg/kg; po; 24 semanas) alivia el desequilibrio metabólico, la inflamación del hígado y reduce los marcadores de lesión renal[7]. En el modelo de ratones SAMP8, tratados con CMS121 (17mg/kg; po; 9 semanass) mostró una reducción significativa de la deriva del umbral de las respuestas auditivas del tronco cerebral y una mayor preservación de las sinapsis de la cinta de células ciliadas internas en el rango de frecuencia media[8].
References:
[1]. Dafre A L, Zahid S, Probst J J, et al. CMS121: a novel approach to mitigate aging-related obesity and metabolic dysfunction[J]. Aging (Albany NY), 2024, 16(6): 4980.
[2]. Dong J, Li M, Peng R, et al. ACACA reduces lipid accumulation through dual regulation of lipid metabolism and mitochondrial function via AMPK-PPARα-CPT1A axis[J]. Journal of Translational Medicine, 2024, 22(1): 196.
[3]. Currais A, Huang L, Petrascheck M, et al. A chemical biology approach to identifying molecular pathways associated with aging[J]. GeroScience, 2021, 43(1): 353-365.
[4]. Currais A, Raschke W, Maher P. CMS121, a novel drug candidate for the treatment of Alzheimer’s disease and age-related dementia[J]. Journal of Alzheimer’s Disease, 2024, 101(s1): S179-S192.
[5]. Albano C, Trifirò L, Hewelt-Belka W, et al. The impact of fatty acid synthase on HSV-1 infection dynamics[J]. PLoS pathogens, 2025, 21(5): e1013068.
[6]. He Y, Wang S, Liu S, et al. MSL1 promotes liver regeneration by driving phase separation of STAT3 and histone h4 and enhancing their acetylation[J]. Advanced Science, 2023, 10(23): 2301094.
[7]. Zahid S, Dafre A L, Currais A, et al. The geroprotective drug candidate CMS121 alleviates diabetes, liver inflammation, and renal damage in db/db leptin receptor deficient mice[J]. International Journal of Molecular Sciences, 2023, 24(7): 6828.
[8]. Pham T B, Boussaty E C, Currais A, et al. Attenuation of age-related hearing impairment in senescence-accelerated mouse prone 8 (SAMP8) mice treated with fatty acid synthase inhibitor CMS121[J]. Journal of Molecular Neuroscience, 2023, 73(4): 307-315.
| Experimentos celulares [1]: | |
Líneas celulares | Células SH-SY5Y |
Método de preparación | Para determinar la citotoxicidad de CMS121, las células SH-SY5Y se sembraron en una placa de cultivo de 96 pozos y se expusieron a concentraciones crecientes de compuestos o dimetil sulfóxido de vehículo (DMSO) al día siguiente. Después de 48 horas de incubación, el número de células viables se determinó utilizando el ensayo de bromuro 3-(4,5-dimetiltiazol-2-il)-2,5-difeniltetrazolio (MTT). Del mismo modo, las células shCTRL y shFASN se cultivaron para confluir. Luego, el medio se reemplazó por medio sin suero, y después de 48 horas, se midió el número de células viables utilizando el ensayo MTT. |
Condiciones de reacción | 5 μM; 48h |
Áreas de aplicación | CMS121 reduce la infectividad de las partículas virales del VHS-1. |
| Experimentos con animales [2]: | |
Modelos animales | Ratones macho db/db |
Método de preparación | A las 5 semanas de edad, los ratones db/db macho y los ratones de tipo salvaje (WT) no tratados (C57BL/6J) fueron alimentados con una dieta de roedores estándar durante 6 meses con o sin la adición de CMS121. Los ratones (12 por grupo) fueron asignados aleatoriamente a un grupo de dieta de tratamiento (db/db + CMS121) o a un grupo de control (db/db). Los ratones WT también fueron evaluados y utilizados como grupo de referencia para resaltar el fenotipo db/db. La ingesta de alimentos correspondía a un consumo promedio de 9,4 mg/kg/día CMS121 durante las primeras 17 semanas de tratamiento y un consumo promedio de 18,8 mg/kg/día CMS121 durante las semanas 18-24. |
Forma de dosificación | 9,4 mg/kg, 18,8 mg/kg; po; 24 semanas |
Áreas de aplicación | El tratamiento a largo plazo con CMS121 alivia el desequilibrio metabólico, la inflamación del hígado y reduce los marcadores de la lesión renal. |
References: | |
| Cas No. | 1353224-53-9 | SDF | |
| Chemical Name | 4-[4-(cyclopentyloxy)-2-quinolinyl]-1,2-benzenediol | ||
| Canonical SMILES | OC1=CC(C2=NC(C=CC=C3)=C3C(OC4CCCC4)=C2)=CC=C1O | ||
| Formula | C20H19NO3 | M.Wt | 321.4 |
| Solubility | 20mg/mL in DMSO, 30mg/mL in DMF | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.1114 mL | 15.5569 mL | 31.1139 mL |
| 5 mM | 622.3 μL | 3.1114 mL | 6.2228 mL |
| 10 mM | 311.1 μL | 1.5557 mL | 3.1114 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)